Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?
Hôpital Saint-Louis, Université Paris-Diderot, Paris, France.
Damien
D
Pouessel
Hôpital Saint-Louis, Université Paris-Diderot, Paris, France.
Hélène
H
Gauthier
Hôpital Saint-Louis, Université Paris-Diderot, Paris, France.
Camille
C
Serrate
University Hospital, Rouen, France.
Christian
C
Pfister
Hôpital Saint-Louis, Université Paris-Diderot, Paris, France stephane.culine@sls.aphp.fr.
Stéphane
S
Culine
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000188:drug therapy*; D015653:Cystectomy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D020011:Protective Agents / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000188:drug therapy*
D014408:Biomarkers, Tumor; D020011:Protective Agents; D016179:Granulocyte Colony-Stimulating Factor